Free shipping on all orders over $ 500

Onatasertib (CC-223)

Cat. No. M4934
Onatasertib (CC-223) Structure
Synonym:

ATG-008

Size Price Availability Quantity
10mM*1mL USD 105  USD105 In stock
2mg USD 80  USD80 In stock
5mg USD 120  USD120 In stock
10mg USD 190  USD190 In stock
50mg USD 700  USD700 In stock
100mg USD 1100  USD1100 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems. CC-223 competitively inhibits the mTOR kinase that targets mTORC1 and mTORC2, prevents upregulation of AKT phosphorylation, differentiating it from the rapalogs. CC-223, with superior physicochem-ical and pharmacokinetic properties, excellent kinase selectivity, demonstrates efficacy across multiple solid tumor models with oral dosing.

Chemical Information
Molecular Weight 397.47
Formula C21H27N5O3
CAS Number 1228013-30-6
Solubility (25°C) DMSO 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Bendell JC,et.al. Cancer. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

[2] Deborah S Mortensen, et al. Mol Cancer Ther. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

Related mTOR Products
Thioether-cyclized helix B peptide, CHBP

Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2.

10-Hydroxy-2-decenoic acid

10-Hydroxy-2-decenoic acid (10-HDA) is the major lipid component of royal jelly produced by honeybees.

mTOR inhibitor-11

mTOR inhibitor-11 is a brain-penetrant mTOR inhibitor (IC50: 21 nM for pS6).

mTOR inhibitor-12

mTOR inhibitor-12 is a selective brain penetrant mTOR inhibitor without genotoxicity risk.

Royleanone

Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis.

  Catalog
Abmole Inhibitor Catalog




Keywords: Onatasertib (CC-223), ATG-008 supplier, mTOR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.